Ozempic for Addiction? The Willpower Debate Just Got Complicated
There is something happening with GLP-1 medications that addiction treatment should be paying attention to. I’m talking about semaglutide and tirzepatide, the medications people know by names like Ozempic, Wegovy, Mounjaro, and Zepbound. They are used for diabetes and obesity, and over the last few years people started describing something that caught my attention for reasons that have very little to do with weight loss.
A lot of people describe the “food noise” getting quieter. They talk about thinking about food throughout the day, planning the next meal while they are still eating the current one, wondering what they are going to eat later, resisting something, eventually eating it, and then starting the whole mental process again. Many of these people do not have alcohol use disorder, substance use disorder, or any other addiction diagnosis. They are describing their relationship with food.
If you work in addiction, that mental pattern sounds very familiar. People with addiction can spend enormous amounts of time thinking about the next drink or the next use, anticipating it, resisting it, bargaining with themselves about it, and returning to the thought again. Craving is part of addiction, and so is the amount of attention and mental energy the substance begins to take up.
Then people taking GLP-1 medications started reporting similar changes with alcohol. Somebody who normally had several drinks might pour one and lose interest, or realize later that they barely thought about drinking that day. There have also been reports involving cigarettes and other compulsive behaviors. That raises an obvious question: are these medications affecting something in the reward system that overlaps with what we see in addiction?
Why Some Rewards Become So Important
Your brain is constantly deciding what deserves your attention and what can be ignored. Certain things stand out because your brain has learned they are important, rewarding, threatening, or relevant.
Scientists use the word salience for this. Salience basically means how strongly something gets tagged by the brain as worth paying attention to. If you are sitting in a crowded restaurant and somebody says your name three tables away, your brain may pick it out immediately because your name has high salience for you.
Alcohol can acquire that kind of importance through repeated reinforcement. The liquor store catches your attention, five o’clock catches your attention, seeing somebody pour a drink catches your attention, and certain people, places, emotional states, or routines can trigger the same response because the brain has learned the association.
Dopamine is involved in this system, although calling dopamine the “pleasure chemical” leaves out a lot. Dopamine is heavily involved in motivation, anticipation, reinforcement learning, and wanting. It helps the brain learn what was rewarding, what predicted that reward, and what should be pursued again.
That distinction between liking and wanting becomes obvious in addiction. Somebody can hate what alcohol is doing to their life and still want alcohol intensely. They can hate the hangovers, anxiety, lying, damage to the marriage, and health consequences, then five o’clock comes around and the craving still shows up.
Researchers are now looking at whether GLP-1 medications can alter some of that reward processing. GLP-1 receptors are present in areas of the brain involved in reward and reinforcement, including areas connected with dopamine signaling.
What Happens if Craving Goes From a Nine to a Three?
Imagine somebody who experiences alcohol craving at a nine out of ten every evening. By late afternoon they are thinking about drinking, deciding they should stay sober, reconsidering ten minutes later, thinking about the liquor store, remembering consequences, bargaining with themselves, and spending a huge amount of energy managing the urge.
That person may have plenty of recovery skills. They can call somebody, go to a meeting, exercise, change environments, practice urge surfing, use distress tolerance, remember consequences, or sit with the urge until it passes. Those strategies still require a lot of cognitive and emotional effort when the craving is intense.
Now imagine the craving comes in at a three. Alcohol crosses their mind, they notice the urge, and they can redirect without spending the next several hours preoccupied with it. Both versions of that person may stay sober, while the amount of effort required is completely different.
Addiction treatment already spends a lot of time helping people manage craving after it appears. A medication that reduces the intensity of craving itself could give somebody more capacity to use the skills they already have.
We Already Use Medication for Craving
Naltrexone has been used for alcohol use disorder for decades. Vivitrol is an extended-release injectable version of naltrexone that is given roughly once a month and can reduce some of the reinforcing effects of alcohol and help reduce relapse risk for appropriate patients.
We also use medications like buprenorphine and methadone for opioid use disorder. They work through different mechanisms and have different clinical purposes, while the larger principle is familiar: change part of the biology contributing to compulsive substance use so somebody has a better chance of stabilizing.
If GLP-1 medications eventually prove useful for alcohol or another substance, they would enter an existing pharmacological conversation. The receptor system is different and the medication is different. Using medication to reduce craving, reinforcement, or relapse risk is already part of addiction medicine.
Why Do We Moralize Weight and Addiction?
There is an interesting parallel with obesity because both conditions get heavily moralized. Somebody can struggle with obesity for years, feel hungry much of the time, think about food constantly, lose weight, regain it, try again, and then take a GLP-1 medication and suddenly find eating much easier to regulate.
People sometimes respond to that with language about cheating, discipline, or willpower. There is a strange cultural expectation that weight loss carries more legitimacy when somebody had to fight hunger the whole way.
Addiction gets a similar treatment. Somebody who spends six hours fighting a craving can be seen as working hard at recovery, while somebody whose medication reduces the craving may be viewed as taking an easier route. I see no clinical value in preserving severe craving simply so somebody can demonstrate effort.
If somebody has impaired glucose regulation and needs medication every week, we treat the physiology. If somebody’s reward system has become heavily conditioned around alcohol and a weekly medication can safely reduce how strongly alcohol captures attention and motivation, that physiology deserves the same seriousness.
Human beings do not have identical reward systems. Genetics, development, reinforcement history, stress, sleep, physiology, environment, and repeated exposure all influence how strongly somebody responds to a reward. One person can drink two glasses of wine at dinner and forget the bottle is sitting there, while another person is already thinking about the third drink halfway through the second.
Responsibility still exists. Biology helps explain the difficulty of the task somebody is responsible for managing.
What the Research Is Showing
In 2025, a randomized clinical trial published in JAMA Psychiatry studied weekly semaglutide in adults with alcohol use disorder. The study included forty-eight participants and lasted nine weeks, so it was small and preliminary. Semaglutide reduced alcohol consumption during a laboratory self-administration procedure, reduced alcohol craving, and improved some weekly drinking outcomes. Cigarette use also decreased among the small subgroup of participants who smoked, while several other drinking outcomes did not significantly change.
Observational studies have also reported associations between GLP-1 medication use and lower rates of alcohol-related problems and several other substance-use diagnoses. Those studies cannot establish causation because people taking these medications may differ in healthcare access, medical monitoring, weight loss, socioeconomic status, health behavior, and other variables.
Larger trials are underway, including Phase 3 research in alcohol use disorder. Those studies should give us better information about who responds, how large the effect is, what happens to craving and drinking behavior, what the side effects look like, and whether benefits last.
The overall research picture also includes mixed findings. A 2026 systematic review and meta-analysis found that several pooled alcohol and nicotine outcomes did not reach statistical significance. The current evidence gives us encouraging signals alongside findings that are less impressive.
What This Could Change in Therapy
The part I find most clinically interesting is the possibility that craving itself may become a more directly modifiable treatment target. Somebody who spends every evening focused on staying sober may have limited capacity to work on the marriage, grief, shame, trauma, loneliness, boredom, identity, or emotional regulation. Once craving becomes more manageable, those areas may become easier to address.
Medication can change the conditions under which psychological treatment happens. We already see this with ADHD, panic disorder, and opioid withdrawal. Symptoms become more manageable, and the person can engage treatment differently.
There are still important questions, including whether reward can be reduced too broadly. Some people taking GLP-1 medications report decreased interest in things beyond food, which raises questions about anhedonia, emotional flattening, dosing, individual differences, and psychiatric history. The clinical goal would be reducing pathological reward seeking while preserving ordinary pleasure and motivation.
Maybe GLP-1 medications eventually become useful treatments for addiction. Maybe the large trials show a modest effect, maybe results vary by substance, or maybe future medications developed from this research become more useful than the drugs we have now.
We do not have the final answer yet. We do have enough evidence to justify taking the question seriously. Addiction treatment has spent decades helping people manage craving once it appears. The possibility that we may also become better at reducing the strength of craving itself is worth following very closely.
